Current intelligence bulletin 11 - dimethylcarbamoyl chloride (DMCC) revised.
NIOSH 1976 Jul; :1-2
Health hazards associated with dimethylcarbamoyl-chloride (79447) (DMCC) were discussed. The results of a bioassay showed that rats exposed by inhalation to 1 part per million DMCC developed squamous cell carcinomas of the nose within 200 days. These tumors were seen in 89 of 93 exposed rats. Earlier studies showed a high incidence of skin tumors and subcutaneous sarcomas along with some capillary tumors in the lung of ICR/Ha-Swiss-mice after subcutaneous and intraperitoneal injection of DMCC. Acute toxic effects of DMCC included irritation of the skin, eyes, and respiratory tract. In the United States (US), the only known uses of DMCC are as an intermediate in the synthesis of pharmaceuticals used in treating myasthenia gravis and as a reagent in the synthesis of carbamates. It was estimated that fewer than 200 persons in the US were potentially exposed to DMCC. Most of these would be intermittent exposures occurring in chemical laboratories. The author concludes that the very high incidence of nasal cancer and the short latency period seen in the most recent animal study suggest that a potentially serious hazard exists for workers exposed to DMCC.
NIOSH-Author; NIOSH-Current-Intelligence-Bulletin-No-11; Organic-compounds; Health-hazards; Carcinogenesis; Bioassays; In-vivo-studies; Laboratory-animals; Risk-analysis; Risk-factors; Occupational-exposure
Numbered Publication; Current Intelligence Bulletin
NTIS Accession No.
(NIOSH) 78-127; CIB 11
National Institute for Occupational Safety and Health